Publications by authors named "S Claudiani"
Article Synopsis
- - Asciminib is a targeted treatment for BCR::ABL1 that minimizes side effects from disrupting other kinases, with a study of 49 patients showing it is generally well tolerated over a median follow-up of 14 months.
- - Most patients (59%) continued treatment, with only 12% stopping due to intolerance; however, treatment cessation was primarily due to intolerance rather than drug resistance (65% vs. 35%).
- - Out of 44 patients evaluated, 66% achieved a complete cytogenetic response, with lower success rates seen in patients with specific genetic variants; further analysis indicated that the drug can influence the growth of certain resistant cancer cell populations.
Article Synopsis
- * Out of 229 patients, the incidence of CV events was found to be 20.9%, with a notably higher occurrence in those with elevated HFA-ICOS risk scores.
- * The findings indicate that the HFA-ICOS risk score effectively predicts the risk of developing CV and ischaemic events during nilotinib therapy, supporting its use for patient risk assessment.
Diagnosing chronic myeloid leukaemia (CML) during pregnancy is rare. Tyrosine kinase inhibitors (TKIs) have traditionally been contraindicated owing to their teratogenicity. Management decisions should consider the risks to mother and foetus of uncontrolled disease and teratogenic medications.
View Article and Find Full Text PDFAdvancements in the management of patients with chronic myeloid leukemia (CML) allowed them to achieve survival comparable with their healthy counterparts. Consequently, their care has widened with growing focus on quality of life, including parenting children. Although tyrosine kinase inhibitors (TKI) are contraindicated in pregnancy given their teratogenic effect, their effect on male fertility is less clear with contradictory results from animal studies and case reports/series.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the likelihood of treatment-free remission (TFR) among Chronic Myeloid Leukemia (CML) patients with different chromosomal characteristics.
- It categorizes patients into groups based on additional chromosomal abnormalities (ACA/Var-Ph group), those with only the classical Philadelphia translocation (c-Ph group), and high-risk ACA (HR-ACA subgroup) or variant Philadelphia translocations (Var-Ph subgroup).
- Findings aim to uncover how these chromosomal variations impact the probability of achieving TFR in CML patients, which is important for treatment decisions.